iMeta | Screening for Covalent mIDH1 Inhibitors from Natural Herbs Using a Click Chemistry-Based Protein Chip Platform

This study provides a novel screening strategy for tumor immunotherapy and natural product drug development, revealing the clinical potential of reversing the immunosuppressive microenvironment by activating CD8+ cells.

 

Literature Overview

This article, titled 'Construction of a clickable probe‐based protein chip platform for discovering covalent mIDH1 inhibitors from natural medicinal extracts,' published in the journal iMeta, systematically explores an innovative platform combining bioorthogonal click chemistry with protein chip technology. It enables high-throughput screening of covalently binding small-molecule inhibitors directly from complex natural plant extracts, successfully identifying Flavokawain C (Flc) as an active component targeting mutant Isocitrate Dehydrogenase 1 (mIDH1).

Background Knowledge

This research aims to address a critical clinical challenge in tumor therapy: the accumulation of the oncometabolite 2-hydroxyglutarate (2-HG) caused by mIDH1 mutations, which leads to abnormal epigenetic modifications and an immunosuppressive microenvironment. Current development of mIDH1 inhibitors faces bottlenecks such as incomplete coverage of mutation subtypes, acquired resistance, and off-target toxicity. Furthermore, traditional high-throughput screening techniques struggle to be directly applied to natural plant extracts with complex compositions. The key innovation of this study lies in constructing a 'Click Chemistry-Protein Chip' (Ccc-Chip) platform that requires no pre-modification of lead compounds. Combined with Differential Scanning Fluorimetry (DSF) for pre-screening, this approach efficiently identifies natural active molecules capable of specifically covalently binding mIDH1 from 110 medicinal plants, providing a new tool to overcome the treatment challenges of drug-resistant tumors.

 

 

Research Methods and Core Experiments

The authors first constructed a protein chip containing various common mIDH1 mutants (e.g., R132H, R132C) and established a competitive binding detection system using the cysteine-targeting probe IAA-yne combined with click chemistry. Through DSF pre-screening and Ccc-Chip confirmation, 110 medicinal plant extracts were subjected to high-throughput screening, ultimately pinpointing extract T96 from the plant Piper methysticum Forst. Subsequently, via preparative liquid chromatography separation, virtual covalent docking, mass spectrometry analysis, and Cellular Thermal Shift Assay (CETSA), the active ingredient was identified as Flavokawain C (Flc). In the mechanism validation phase, the research team utilized mIDH1-driven xenograft models and orthotopic liver cancer models, combined with single-cell sequencing (scRNA-seq) technology, to deeply analyze the impact of Flc on CD8+ cell infiltration and function within the tumor microenvironment.

Key Conclusions and Perspectives

• Flc specifically covalently binds to the Cys269 residue of mIDH1, significantly reducing the levels of the oncometabolite 2-HG within tumor cells. This finding provides a clear lead compound for developing covalent inhibitors targeting metabolic tumors.
• By restoring the cGAS-STING signaling pathway, Flc effectively reverses the immunosuppressive state in mIDH1-mutant tumors, significantly increasing the infiltration ratio of CD8+ cells in tumor tissues and enhancing their cytotoxic function, suggesting potential synergistic efficacy when combined with immune checkpoint inhibitors.
• The Ccc-Chip platform successfully achieved the direct screening of covalent active molecules from complex natural extracts, demonstrating the broad application prospects of this strategy at the intersection of natural product chemistry and functional proteomics, offering an efficient pathway for discovering new drugs against difficult-to-drug targets.

Research Significance and Prospects

This discovery has profound implications for the field of drug development, particularly by providing a replicable technical paradigm for screening covalent drugs against high-mutation-rate targets. In terms of clinical monitoring, the study suggests that 2-HG levels and the functional status of CD8+ cells can serve as key biomarkers for evaluating the efficacy of mIDH1 inhibitors. Additionally, the model system established in this research offers new ideas for disease modeling; utilizing immunocompetent mouse models combined with single-cell sequencing allows for a more accurate assessment of a drug's ability to remodel the tumor immune microenvironment, thereby accelerating the process from laboratory discovery to clinical translation.

 

 

Conclusion

Through the innovative Ccc-Chip platform, this study successfully identified the covalent inhibitor Flc from natural plants. It not only addresses the challenges of drug resistance and immunosuppression in mIDH1-mutant tumor therapy but also demonstrates the immense potential of natural products in modern precision medicine. Flc lowers 2-HG levels by targeting the Cys269 residue, thereby activating the cGAS-STING pathway and recruiting CD8+ cells. This dual mechanism offers a new combination therapy strategy for tumor immunotherapy. From laboratory screening to in vivo efficacy validation, this study comprehensively presents the translational pathway from natural product discovery to preclinical evaluation. It emphasizes the foundational role of combining high-throughput screening technologies with immune microenvironment analysis in tackling complex cancers, laying a solid foundation for the future development of safer and more efficient covalent targeted drugs and immunotherapeutic combination therapies.

 

Zhao Cui, Jiameng Li, Caifeng Li, Hongjun Yang, and Peng Chen. Construction of a clickable probe‐based protein chip platform for discovering covalent mIDH1 inhibitors from natural medicinal extracts. iMeta.